Nancy Delgado1*, Niels Wacher2 and Diana Navarrete3
1Deparment of Hematology, XXI Century National Medical Center, Mexico
2Medical Research Unit in Clinical Epidemiology, XXI Century National Medical Center, Mexico
3Blood Bank, La RAZA Medical Center Specialty Hospital, Mexico
Objective: To evaluate and compare the performance of the EUTOS and Sokal prognostic scales, to predict failure to obtain cytogenetic response at 6 months, in patients with Chronic Myeloid Leukemia in chronic phase treated with imatinib, from the Hematology department of the XXI Century National Medical Center.
Material and Methods: The study included 133 adult patients, diagnosed with Chronic Myeloid Leukemia (CML) between January-2006 and July-2018. They received treatment with Imatinib and the Sokal and EUTOS scale were applied and a Complete Cytogenetic Response (CCyR) was evaluated at 6 months of treatment, to know if any of these scales had better performance.
Results: With the Sokal scale, the distribution was 36.8% low risk, 42.9% intermediate risk, and 20.3% high risk. With the EUTOS scale, 68.4% low risk and 31.6% high risk. 59.3% of patients with high risk of Sokal did not achieve CCyR at 6 months and 52.4% of patients with high risk of EUTOS, so the Sokal scale identifies a greater proportion of high-risk patients who will not achieve CCyR at 6 months. However, the difference was not statistically significant (p=0.072). In the graphic representation of the ROC Curve (at 6 months of treatment), it is observed that both prognostic scales have very similar discrimination power and the area under the curve was statistically significant. For the case of Sokal (area 0.646, p=0.005, CI 95% 0.546- 0.747) and for EUTOS (area 0.726, p=0.000, CI 95% 0.639-0.818).
Conclusion: Both scales (Sokal and EUTOS) help us to discriminate between patients who achieved CCyR at 6 months and those who did not obtain this response.
Sokal score; Eutos score; Chronic myeloid leukemia; Complete cytogenetic response
Delgado N, Wacher N, Navarrete D. Performance of the EUTOS and Sokal Prognostic Scales, To Predict Optimal Response after 6 Months of Imatinib Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase. Clin Oncol. 2021;6:1852..